Three small molecule inhibitors of BET have been investigated in pre-clinical models and have been shown to downregulate MYCN expression, induce cell cycle arrest and apoptosis in neuroblastoma cells and inhibit tumor growth in mouse models [14,15]. This evidence concerns the gene MYCN and neuroblastoma.